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Abstract: Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer 
drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation 
of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a 
non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it 
has recently demonstrated clinical responses in adults with refractory and relapsed acute myeloid 
leukemia (AML), and in older adults with newly diagnosed poor-risk AML, its activity was far 
less than anticipated. However, it appears that tipifarnib as a single agent may be important in 
selected groups of patients. Much remains to be learned to optimize such therapy in patients 
with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing.
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Introduction
The outcome of therapy for acute myeloid leukemia (AML) has improved over the 
recent years, mainly in patients of younger age. However, the challenges in this area 
have remained considerable. AML is primarily a disease of the elderly and this patient 
population has a very poor prognosis, which is attributed to having disease that is 
inherently more resistant to current standard cytotoxic agents in relationship with 
acquired genetic characteristics of the leukemia, and/or relatively poor tolerance of 
these agents because of comorbidity and reduced tolerance of adverse effects. The 
unmet therapeutic need is therefore greatest among patients with AML of older age, in 
whom response rates are comparatively low (50% for those older than 60 years old), 
relapse rates are exceedingly high (more than 85%), and long-term survival rates are 
less than 10% (Löwenberg et al 1999; Rowe 2000).
The traditional chemotherapeutic approach to the patient with AML has been based 
on treatment with a combination of an anthracycline (or anthracenedione) with cytarabine. 
New drugs are currently in early clinical development with the aim of circumventing 
chemotherapy resistance. Biological insight into the mechanisms of defective molecular 
pathways in malignant cells has resulted in the identiﬁ  cation of novel targets for drug 
development. Farnesyltransferase inhibitors (FTIs) represent a new class of signal-
ing inhibitors that may inhibit critical growth and survival signals. These agents are 
competitive inhibitors of intracellular farnesyl protein transferase (FTase), an enzyme 
that catalyzes the transfer of a farnesyl moiety to the cysteine terminal residue of a 
substrate protein. A host of intracellular proteins are substrates for prenylation via 
Ftase. Interrupting the normal prenylation process of these substrate proteins has been 
shown useful for inhibiting cellular events that are governed by them (End 1999).
Four main approaches to blocking FTase have been designed: (i) competition with 
the farnesyl pyrophosphate (FPP) group using synthetic analogs, (ii) competition with 
the target protein or its CAAX binding site or both using peptides (peptidomimetics), Biologics: Targets & Therapy 2007:1(4) 416
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(iii) competition with FPP and CAAX using analogs that com-
bine features of both the FPP analogs and peptidomimetics, 
and (iv) competition with protein/CAAX using nonpeptide 
analogs (Rowansky et al 1999).
At least six FTIs have been tested in clinical trials, 
including BMS-214662 (Bristol-Myers Squibb, Princeton, 
NJ, http://www.bms.com), L778123 (Merck and Co., Inc., 
Whitehouse Station, NJ, http://www.merck.com), lonafarnib 
(experimental name, SCH66336; Sarasar™; Schering-Plough 
Corporation, Kenilworth, NJ, http://www.sch-plough.com), 
FTI-277 (Calbiochem, EMD Bio-Sciences, San Diego, http://
www.emdbiosciences.com), L744832 (Biomol International 
L.P., Plymouth Meeting, PA, http://www.biomol.com), 
and tipifarnib (experimental name, R115777; Zarnestra®; 
Ortho Biotech Products, L.P., Bridgewater, NJ, http://www.
orthobiotech.com), which is the most advanced FTI in clinical 
development (Brunner et al 2003).
This review outlines the characteristics of tipifarnib and 
its potential mechanisms of action, and describes the early 
results with this FTI in the treatment of AML.
Tipifarnib
Tipifarnib belongs to the nonpeptidomimetic FTIs. It is a 
4,6-disubstituted-1-methylquinolin-2-one derivative that was 
obtained by optimization of a quinolone lead identiﬁ  ed from 
compound library screening (Venet et al 2003) (Figure 1). 
Tipifarnib is synthesized by the condensation of the anion 
of 1-methylimidazole with a 6-(4-chlorobenzoyl) quinolone 
derivative, followed by dehydration. The quinolone interme-
diate was prepared in four steps by cyclization of N-phenyl-
3-(3-chlorophenyl)-2-propenamide, acylation, oxidation and 
N-methylation. Tipifarnib was identified from Janssen’s 
ketoconazole and retinoic acid catabolism programs as a key 
structural feature into Ras prenylation process. Tipifarnib is a 
potent inhibitor of FTase in vitro and is orally active in a variety 
of animal models (End et al 2001). Tipifarnib was the ﬁ  rst FTI 
tested in a clinical trial. It is reasonably well tolerated in man 
and requires twice-daily dosing to obtain effective plasma 
concentrations (Kurzrock et al 2004). Phase I studies showed 
that myelosuppression and neurotoxicity were dose-limiting 
toxicities. Gastrointestinal toxicities and fatigue were observed 
as well (Zujewski et al 2000; Crul et al 2002).
Possible mechanisms of tipifarnib 
biological activity
FTIs were initially developed to speciﬁ  cally inhibit the 
activity of oncogenic ras in tumor cells by inhibiting the 
farnesylation of Ras. Evidence pointing to the importance 
of ras in myeloid leukemogenesis emanates from an in vivo 
model, in which irradiated mice, reconstituted with bone 
marrow transfected with activated N-ras, developed AML 
and myelodysplastic syndrome (Mackenzie et al 1999). At 
present, the mechanisms behind the anti-tumorigenic effects 
of FTIs appear complex. The role of ras inhibition in the 
antitumor activity of tipifarnib is a topic of debate, and other 
farnesylated targets have been identiﬁ  ed.
The Ras protein
The family of ras genes consists of three functional genes, 
H-ras, K-ras, and N-ras. These genes are highly homolo-
gous and encode for four 21-kDa proteins: H-Ras, the splice 
variants Ki4A-Ras and Ki4B-Ras, and N-Ras, respectively. 
The N-ras gene is predominantly mutated in AML (30%) 
(Bos 1989).
Ras proteins are GTPases that play a central role in growth 
signal transduction pathways. Following isoprenylation in the 
cytosol, the Ras protein migrates to the cell membrane, where it 
is capable of activating downstream signaling events (End et al 
1999; Khosravi-Far et al 1992; Cox et al 2001). Ras proteins 
contain 188 or 189 amino acids and exhibit high sequence 
homology, with the ﬁ  rst 86 amino acids being identical, the 
next 78 having 79% homology, and the following 25 amino 
acids being highly variable. The ﬁ  nal four amino acids play 
an important role in specifying subcellular localization of 
the Ras protein. All Ras proteins have a speciﬁ  c amino acid 
sequence motif at the COOH-terminal region, commonly 
referred to as the CAAX box, in which C represents a cysteine 
residue; AA represent aliphatic amino acids, usually valine, 
leucine, or isoleucine; and X is either methionine or serine. The 
membrane-targeting domain contains cysteine palmitoylation 
sites in H-Ras, N-Ras, and K-Ras4A or a polylysine domain 
in K-Ras4B. Palmitoylation or the presence of a polybasic 
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Figure 1 Structure of tipifarnib: R115777(R)-6-amino[(4-chlorophenyl)(1-methyl-
1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolone. Tipifarnib 
is a farnesyltransferase inhibitor developed by Johnson & Johnson Pharmaceuti-
cal Research and Development LLC. It is a nonpeptidomimetic oral quinolone 
analog of imidazole-containing heterocyclic compounds. It competitively inhibits 
the CAAX binding site of farnesyl transferase. The imidazole group is the central 
pharmacophore and the imidazole may interact with the coordination structure 
of the zinc catalytic site.Biologics: Targets & Therapy 2007:1(4) 417
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domain is essential for efﬁ  cient transportation to the plasma 
membrane. The transfer of a farnesyl group is mediated by 
the enzyme FTase, whereas transfer of a geranyl group is 
mediated by geranylgeranyl transferase (Figure 2). Ras protein 
isoforms differ in their afﬁ  nity for speciﬁ  c isoprenyl groups. 
K-Ras is a higher afﬁ  nity substrate for Ftase than H-Ras (Zhang 
et al 1997). Both N-Ras and K-Ras, but not H-Ras, are weak 
substrates for GGTase-1. In cell culture, FTIs prevent H-Ras 
farnesylation. In contrast K- and N-Ras are alternatively 
prenylated by GGTase-1 in FTI-treated cells (Whyte et al 
1997). While membrane bound and upon binding an active 
deoxyguanosine triphosphate (GTP), Ras transduces the sig-
nal to various effector proteins (Figure 3). Subsequently, it 
becomes inactivated through conversion of GTP to an inactive 
guanosine diphosphate (GDP) by an intrinsic GTPase (Boguski 
and McCormick 1993). A point mutation in codon 12, 13, or 
61 of the ras gene leads to insensitivity of Ras to the GTPase-
activating protein (GAP) and a signiﬁ  cantly lower GTPase 
activity, resulting in deranged or aberrant signal transduction 
(Lowy and Willumsen 1993).
The pathways that are controlled by activated Ras are 
designed to prolong cell survival and promote cell prolifera-
tion (Figure 4).
One key pathway is the Raf-MEK-MAPK cascade. The 
Raf protein is a serine-threonine protein kinase that binds 
Ras to become active. Raf is able to initiate a downstream 
cascade of phosphorylation, ultimately resulting in the 
phosphorylation of mitogen-activated protein kinase 
(MAPK) also known as extracellular signal-regulated 
kinase (ERK), localized in the nucleus where it activates 
transcription factors involved in the control of cellular pro-
liferation and apoptosis (Davies 1995; Bonni et al 1999). 
Transcription-independent mechanisms may also account 
for the pro-survival effect of this pathway via phosphoryla-
tion and subsequent inactivation of the proapoptotic BAD 
(Bcl-2-associated death promotor) protein. MAPK may be 
overexpressed or constitutively activated in hematopoietic 
malignancies, and may be a viable indirect target for FTIs.
The PI3K/AKT pathway occupies a critical position in 
the transduction of signals beginning with groth-stimulating 
cytokines and ending with cell proliferation and survival 
(Burgering and Coffer 1995; Klippel et al 1998). One trigger 
for this pathway is activated Ras, which interacts with PI3K 
in the phosphorylation and activation of the serine-threonine 
kinase AKT, which phosphorylates substrates involved in cell 
proliferation and survival following DNA damage or other 
cellular stresses. Vascular endothelial growth factor (VEGF), 
a pivotal growth and survival factor for leukemias, is also 
produced by the Ras-dependent AKT pathway (Mazure et al 
1997). Other substrates, including those involved in cell cycle 
regulation and DNA repair, are inhibited as a result of AKT 
phosphorylation.
The Rho proteins are Ras-related GTP-binding pro-
teins that coordinate growth factor-induced assembly of 
intracellular focal adhesions and actin stress ﬁ  ber formation 
(Ridley and Hall 1992). Posttranslational prenylation 
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Figure 2 Ftase catalyses the farnesylation step by recognizing the CAAX motif of the Ras C-terminus and transferring a 15-carbon farnesyl isoprenoid from farnesyl 
diphosphate to form a thioether bond with the Ras cysteine. In another principal prenylation reaction, protein geranylgeranyl transferases transfer either one or two 
20-carbon geranylgeranyl isoprenoids from geranylgeranyl diphosphate to proteins (Rowinski et al 1999).Biologics: Targets & Therapy 2007:1(4) 418
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occurs in these proteins, leading to both farnesylated and 
geranylgeranylated forms. The RhoB isoform is expressed 
at highest levels during the S-phase of the cell cycle. This 
small GTPase is involved in regulation of endosomal traf-
ﬁ  c (Ellis and Mellor 2000). FTI treatment leads to a shift 
toward geranylgeranylation of RhoB and altered cellular 
localization and function. As such, Rho may be a relevant 
target for FTI therapy. The geranylgeranylated form of 
RhoB accounts for up to 70% of the total RhoB protein in 
untreated cells. In the presence of FTIs, all of the cellular 
RhoB is geranylgeranylated (Lebowitz et al 1997). Inhibi-
tion of RhoB farnesylation may contribute to the antitumor 
activity of FTIs. Recently, it has been found that the gera-
nylgeranylated form of RhoB inhibits expression from the 
cyclin B promotor and that under low serum conditions 
FTI treatment reduced cyclin B levels, leading to cell cycle 
arrest and apoptosis (Kamasani et al 2004).
Alternative targets
While it is becoming clear that FTIs only partly target 
Ras, how these agents selectively target leukemic cells has 
emerged as an important question. In the proteome, there are 
close to 300 proteins with a CAAX motif that are potentially 
farnesylated and over 20 proteins have been proven to be 
farnesylated (Kho et al 2004). Proteins that are not gera-
nylgeranylated in FTI-treated cells are more likely to play a 
critical role in the biological response to FTIs.
CENP-E and CENP-F
CENP-E is a centromere-associated kinesin motor protein that 
functions in microtubule attachment to kinetochores, involved 
in the segregation of sister chromatids during mitosis. CENP-E 
is also essential for positioning chromosomes at the metaphase 
plate (Yao et al 1997). CENP-F is a cell cycle-regulated chro-
mosome passenger protein that functions in mitosis (Liao 
et al 1995). FTIs may interfere with bipolar spindle forma-
tion during transition from prophase to metaphase in mitosis. 
Centromere proteins CENP-E and CENP-F are substrates for 
FTase but not geranylgeranyl transferase I (Ashar et al 2000). 
This mechanism contributes to the observed enhancement of 
antineoplasic activity of the combination of tipifarnib with 
antimicrotubule agents (Zhu et al 2005).
Rheb
Another potential target for FTI action include Rheb, a 
GTPase with two forms Rheb1 and Rheb2. Downstream 
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Figure 3 Ras processing and targeting to the plasma membrane. The cytosolic FTase catalyzes the covalent addition of farnesol from farnesylpyrophosphate (FPP) to the 
cysteine residue of the carboxyl terminal CAAX tetrapeptide sequence (where C is a cysteine residue, A an aliphatic amino acid, and X either methionine or serine). In the 
endosome/Golgi membranes, transferase enzymes catalyze the removal of the AAX residues and the methylation of the resulting farnesyl-cysteine residue. A “second signal” 
is required to complete the translocation of Ras from endosomal membranes to the plasma membrane (Cox et al 2001).Biologics: Targets & Therapy 2007:1(4) 419
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from AKT in the signaling pathway, the target of rapamycin 
occupies a central position. AKT can inhibit the tuberous 
sclerosis TSC1/TSC2 (hamartin/tuberin) complex that 
turn off Rheb, which can activate the mamalian target of 
rapamycin/S6 kinase signaling (mTOR signaling). Rheb 
proteins are farnesylated. Rheb1 and Rheb2 are in vitro 
substrates for Ftase, but not GGTase-1, and treatment of cells 
with FTIs completely inhibits prenylation of Rheb. Activa-
tion of Rheb stimulates growth and cell cycle progression 
(Aspuria and Tamanoi 2004; Gau et al 2005). Inhibition of 
Rheb farnesylation may play a role in FTI enhancement of the 
antitumor response to other chemotherapeutics (Basso et al 
2005). FTIs lead to a more complete of the Rheb signaling 
pathway than do mTOR/Raptor inhibitors such as rapamycin. 
FTIs inhibit signaling downstream of Rheb, including both 
mTOR/Raptor, which regulates growth, and mTOR/Rictor, 
which regulates the actin cytoskeleton.
RhoB
Rho proteins are involved in remodeling of actin cytoskeleton 
and in integrin-mediated cell adhesion: RhoA plays a role in 
the regulation of actomyosin contractility, RhoB regulates 
cytokine trafﬁ  cking, and RhoC may be important in cell loco-
motion (Wheeler and Ridley 2004). RhoB can be prenylated. 
When farnesylation is blocked by FTIs, a shift of RhoB to 
RhoB geranylgeranylated occurs (Du and Prendergast 1999; 
Liu et al 2001). It has been suggested that the short half-life 
of RhoB corresponds to the rapid morphological reversion 
observed in some FTI-treated cells (Lebowitz et al 1997).
PTP-CAAX/PRL
The PTP-CAAX or PRL family of protein tyrosine phos-
phatases plays a role in regulating cell growth and mitosis. 
The PRL family includes three members, all of which are 
farnesylated proteins (Cates et al 1996). Cells ectopically 
expressing not prenylated PRL display defects in mitosis and 
cytokinesis characterized by chromosome bridges and lag-
ging chromosomes. Farnesylated PRL is required for proper 
spindle dynamics. Inhibition of PRL farnesylation may in part 
account for FTI-induced accumulation of cells in the G2/M 
phase of the cell cycle (Wang et al 2002).
HDJ
Human DnaJ homologs include HDJ2, HSJ1, and HDJ1/Hsp40. 
These proteins serve as co-chaperones and stimulate the ATPase 
activity of Hsp70 (Nagata et al 1998). They increase the level 
of Hsp70 in its ADP-bound form that as greater afﬁ  nity for 
unfolded polypeptide subtrates. This facilitates the folding of 
proteins and Hsp70-mediated nuclear trafﬁ  cking. Although the 
functional signiﬁ  cance of HDJ2 farnesylation remains unclear, 
HDJ2 prenylation status has been used as a marker for FTase 
inhibition in clinical trials. Studies suggest that farnesylation may 
regulate the activity, localization, or complex formation that is 
required for YDJ1 (the Saccharomyces cerevisiae homolog of 
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Figure 4 Simpliﬁ  ed scheme of Ras activation. Ras proteins are activated by tyrosine kinase receptors as well as cytokine receptors. Once activated, GTP-bound Ras binds 
to effector molecules such as Raf kinase, Ral-GEF and PI3K. Ras signaling through Raf leads to sequential activation of MEK and ERK, resulting in cellular proliferation, 
differentiation and cell cycle progression. Ras activation of Ral-GEF causes activation of Rho, which induces stress ﬁ  ber formation and actin polymerization/depolymeriza-
tion. Activation of PI3K recruits PDK1/2 and AKT to the plasma membrane, resulting in activation of transcription factors, activation of glycogen synthetase, increased cell 
survival, and entry into the cell cycle by activating cyclin D1 (Morgan et al 2003).Biologics: Targets & Therapy 2007:1(4) 420
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HDJ2) function (Caplan et al 1992). There is little work reported 
to date on the functional consequences of blocking HDJ2 farne-
sylation in human cells.
Nuclear lamins
The nuclear lamina consists of lamin proteins that are required 
for nuclear envelope assembly. Lamin B was one of the ﬁ  rst 
proteins shown to be modiﬁ  ed by prenylation. Lamin A is also 
farnesylated. Although the functional role of lamin farnesyl-
ation remains unclear, it is though to play a role in targeting 
prelamin A to the nuclear membrane, where mature lamin A is 
released by the action of a protease (Sinensky et al 1994). The 
accumulation of unfarnesylated prelamin A can be detected 
and provides another marker for FTase inhibition. The func-
tional role of lamin farnesylation remains unclear.
Additional farnesylated proteins
A number of other farnesylated proteins have been identiﬁ  ed 
that may contribute to the biological activity of FTIs. These 
include other small GTPases: RhoD, RhoE, Rho6, Rho7, 
TC10, all of which have been demonstrated to be substrates 
for alternative prenylation by GGTase-1 (Basso et al 2006). 
Additional farnesylated proteins include the GTPase RRP22 
and the prostacyclin receptor (Elam et al 2005).
Effects on cell cycle progression 
and on apoptosis
The inhibition of protein farnesylation interrupts the func-
tions of diverse proteins that help to move the cell through 
its division cycle. FTIs may also impede the farnesylation 
and function of the kinetochore-binding centromeric proteins 
(CENPs) E and F, which exert their maximal effets in the 
G2 and M phases of the cell cycle (Ashar et al 2000). FTIs 
block the growth of a variety of leukemia cell lines both in 
vitro and when grown as xenografts in vivo. Tumor growth 
is inhibited by tipifarnib in these models over a dose range of 
25-100 mg/kg twice daily (bid) (End et al 2001). FTIs induce 
G2/M accumulation and G1 arrest (Suzuki et al 1998) in both 
a p53-dependent and -independent fashion. FTIs are potent 
activators of apoptosis in Ras-transformed cells if attach-
ment to substratum is prevented. This apoptotic response is 
blocked by BCL-XL and inhibited by a myristylated form of 
RhoB (Lebowitz et al 1997b).
Preclinical and biological studies 
of tipifarnib in leukemia
The preclinical studies of FTI activities against a wide range 
of tumor cell types have demonstrated that the action of FTIs 
is not dependent upon the presence of ras mutations. In most 
preclinical models, FTIs induce tumor growth inhibition, 
when used as monotherapy (End et al 2001; Cox and Der 
2002; Lancet and Karp 2003). Several genes involved in 
FTI biology were identiﬁ  ed as being modulated following 
treatment with tipifarnib in addition to pathways involved 
with cytoskeletal organization, cell signaling, immunity, and 
apoptosis (Raponi et al 2004). Microarray analysis of pre-
treatment bone marrow samples from patients with relapsed 
and refractory AML identiﬁ  ed 8 genes that were associated 
with response to tipifarnib (Raponi et al 2007). The most 
robust marker was the guanine nucleotide exchange factor 
AKAP13, which showed increased expression in patients 
who were resistant to tipifarnib.
Clinical trials in acute myeloid 
leukemia
First trials in advanced cancer
Several single-agent phase I studies with tipifarnib have been 
reported. In an initial study, tipifarnib was dosed orally bid. 
for 5 days every two weeks. The maximum tolerated dose 
with this schedule was identiﬁ  ed as 500 mg bid. Adverse 
events included nausea, vomiting, and fatigue. Myelosup-
pression was mild (Zujewski et al 2000). Another study 
explored a more prolonged schedule of 28 days of treatment 
followed by 1–2 weeks of rest. The maximum tolerated dose 
was 300 mg bid. and myelosuppression was dose-limiting 
(Punt et al 2001). A third study used tipifarnib at 300 mg bid. 
as continuous treatment. Myelosuppression and neurotoxicity 
were dose-limiting, but one partial response was observed 
(Crul et al 2002).
Phase I and phase II studies with tipifarnib 
as a single agent in AML
The most promising clinical results with tipifarnib have been 
observed in hematologic malignancies, including AML. 
In a phase I study of 35 adults with refractory or relapsed 
acute leukemia, 10 patients responded including 2 with 
complete responses. Patients were treated for 21 days, and 
dose limiting toxicities, including neurotoxicity, nausea and 
myelosuppression, were observed at the 1,200 mg bid. dose 
(Karp et al 2001). Responses were independent of ras muta-
tional status. The optimal inhibition of protein farnesylation 
was obtained at 300 mg bid. for 21 days of a 28 day cycle 
(Zimmerman et al 2004). Clinical activity was conﬁ  rmed in 
myelodysplastic syndromes (MDS), a pre-leukemic disease. 
In 21 patients with MDS, tipifarnib given at 300 mg bid. (3 Biologics: Targets & Therapy 2007:1(4) 421
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weeks on/1 week off) resulted in one complete response, 2 
partial responses, and 3 hematologic improvements (Kurz-
rock et al 2003). Responses were also observed when using 
a 4 week on/2 week off schedule (Kurzrock et al 2004). 
Intermittent dosing (bid. on alternative weeks) has also been 
shown more effective, in that higher doses (600 mg) can be 
given without toxicities (Lara et al 2005). In the presence 
of poor risk features, including older age, unfavorable cyto-
genetics, antecedents of MDS, and properties of multidrug 
resistance, the likelihood of disease-free survival (DFS) at 
one year is less than 20% (Leith et al 1997; Lancet et al 2000). 
In a phase 2 study, 82 patients with poor-risk MDS received 
tipifarnib (300 mg twice daily) for the ﬁ  rst 21 days of each 
28-day cycle. Twenty-six patients (32%) responded and 37 
(45%) had stable disease. The median response duration was 
11.5 months, and the median time to progression was 12.4 
months (Fenaux et al 2007).
In patients older than 75 years, survival was in the 
order of 3 to 4 months, clearly highlighting the need for 
novel therapies in this group of patients (Appelbaum et al 
2006; Kantarjian et al 2006). Activity has been reported 
with single-agent tipifarnib in poor-risk AML patients 
(Lancet et al 2007). In this study, a majority of patients had 
antecedents of MDS. Complete remission was achieved 
in 22 patients (14%) and partial remission or hemato-
logic improvement occurred in 15 patients, for an overall 
response rate of 23%. Achievement of CR appeared to 
impart a major survival beneﬁ  t. The median of DFS was 
7.3 months and the median survival of complete respond-
ers was 18 months (Table 1). Tipifarnib was relatively well 
tolerated. Drug-related nonhematologic serious adverse 
events were observed in 47% of cases. The more frequently 
encountered were infection, gastrointestinal disturbances, 
renal insufﬁ  ciency, and skin rash. Neurologic toxicity was 
rare and non-disease-related early mortality rate was only 
7%, that compares favorably with death rates observed with 
induction chemotherapy in the elderly. Furthermore, because 
tipifarnib was administered orally, the median number of 
days spent in the hospital was low. Adverse karyotype and 
poor performance status correlated negatively with survival. 
Inhibition of farnesylation of the surrogate protein HDJ-2 
occurred in a large majority of cases. Baseline levels of 
phosphorylated mitogen-activated protein kinase and AKT 
did not correlate with clinical response.
Another large study assessed the efﬁ  cacy of tipifarnib as 
single-agent but in refractory or relapsing AML (Harous-
seau et al 2007) and conﬁ  rmed the antileukemic activity 
initially observed in the phase I setting (Karp et al 2001). 
In this study, only 11 of 252 patients (4%) achieved com-
plete remission (9 patients) or complete remission with 
incomplete platelet recovery (2 patients). Nineteen patients 
(8%), including those who achieved complete remission, 
achieved a reduction in bone marrow blasts to less than 5%. 
Bone marrow blasts were reduced by 50% in an additional 8 
patients (Harousseau et al 2007) (Table 1). Despite a disap-
pointingly low response rate, it was especially interesting 
to note the observation of complete remissions in cases 
presenting unfavorable cytogenetics. Myelosuppression 
was the most common adverse event. No new side effects 
related to tipifarnib treatment were identiﬁ  ed. Treatment-
related mortality was lower than that associated with 
standard induction chemotherapy. Results from this study 
suggest the consideration of combining tipifarnib with other 
antileukemic therapies.
Preclinical work showed that farnesyltransferase remained 
inhibited for seven days after tipifarnib, suggesting an alter-
nate week dosing schedule. In a phase I dose escalation trial 
in AML on a week on week off schedule, 30 patients were 
accrued (Kirschbaum et al 2006). It was showed that greater 
than two fold increase in tipifarnib dosing can be tolerated on 
this dosing schedule with enhanced efﬁ  cacy. Similar results 
were observed in MDS (Kurzrock et al 2006).
A recent study has shown that the median overall survival 
of older patients treated with tipifarnib was in fact longer than 
that of patients treated with the combination of idarubicin 
with cytarabine or idarubicin with other agents (Estey et al 
2006). Despite these initial encouraging results, in 2005 the 
Oncology Drugs Advisory Committee rejected the approval 
of tipifarnib for the treatment of elderly patients with newly 
diagnosed poor-risk AML, citing an insufﬁ  cient complete 
response rate. The relatively low toxicity proﬁ  le may allow 
for extended therapy to maintian disease control, quality of 
life, and survival, even if full response is not achieved. The 
phase III trial (R115777-AML-301 trial) comparing tipifarnib 
with best supportive care may provide the necessary conﬁ  r-
matory data for approval. Tipifarnib in maintenance therapy 
during minimal residual disease has also been explored 
(R115777-INT-21 trial). Oral tipifarnib (400 mg bid for 2/3 
weeks) was begun after start of ﬁ  nal consolidation cycle and 
given for up to 36 cycles to 36 adults with poor risk AML 
(Karp et al 2006). Tipifarnib was well tolerated. However, 
dose reductions for myelosupression occurred in 53% and 6% 
needed platelet transfusions. A total of 15 patients progressed 
while on tipifarnib at median of 6.5 months from complete 
remission. There was no negative impact on reinduction 
chemotherapy at relapse.Biologics: Targets & Therapy 2007:1(4) 422
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Tipifarnib combined with other agents 
in AML
Trials that combine tipifarnib with other agents, most par-
ticularly cytotoxics, are ongoing. Indeed, pre-clinical data 
suggest that tipifarnib may be synergistic with some che-
motherapeutic agents. In a phase I/II study in 74 adults with 
previously untreated AML or high-risk MDS, tipifarnib 
(200 mg bid or 300 mg bid for 21 days every 28 days) was 
combined with idarubicin (12 mg/m2/day for 3 days) and 
cytarabine (1.5 mg/m2/day for 4 days) (Alvarez et al 2006). 
A high rate of response was observed in AML (77%; 65% 
achieved complete remission and 12% complete remis-
sion with incomplete platelet recovery), with, however, an 
increased incidence of diarrhea and hyperbilirubinemia. 
Response by cytogenetics was 86% for diploid, 76% for 
monosomy 5 or 7, and 68% for other abnormalities. Patients 
achieving complete remission received 5 courses of consoli-
dation with idarubicin (8 mg/m2/day for 2 days), cytarabine 
(0.75 mg/m2/day for 3 days), and tipifarnib (300 mg bid for 
14 days) every 4-6 weeks. Maintenance was with tipifarnib 
300 mg bid for 21 days every 4–6 weeks for 6 months.
In another phase I trial tipifarnib was combined with 
oral etoposide (Karp et al 2006b). This was conducted in an 
attempt to increase complete remission rates in elderly AML 
patients aged more than 70. Both tipifarnib and etoposide 
were given with escalating doses (300 mg to 600 mg bid for 
tipifarnib, and 100 mg to 200 mg/day for 6 days for etoposide) 
and 14 versus 21 days of tipifarnib every 28–63 days. While 
43% of patients required hospitalization during the ﬁ  rst cycle 
for a median of 7 days, overall hospitalization rate for all 
cycles was 28%. Complete remission was achieved in 21% 
of cases and partial remission or hematologic improvement 
in 20%. All patients who achieved complete remission have 
done so within two cycles. The oral regimen was therefore 
tolerable and feasible on an outpatient basis, with the sugges-
tion of improvement of response rates over tipifarnib alone. 
Direct comparisons with chemotherapy alone are warranted 
in randomized trials.
Conclusion
FTIs exhibit encouraging signs of clinical activity in patients 
with AML. However, standard response criteria, which have 
proven valuable in the clinical development of cytotoxic 
agents, cannot be applied to FTIs, as with other new classes 
of targeted signal transduction inhibitors. This suggests 
that aggressive disease may not be appropriate settings to 
explore activity of FTIs. Greater activity is anticipated in the 
maintenance setting. New settings in which single-agent FTI 
therapy should be investigated include previously untreated 
AML and minimal residual disease. AML patients who are 
older than age 60 experience extremely poor long-term out-
comes. New targeted agents like the FTIs offer the potential 
of increased therapeutic index, an important consideration 
in older patients with AML. One asset of this class of 
agents for this patient population is a toxicity proﬁ  le that is 
very acceptable. FTIs might be administered on a chronic 
dosing schedule, either alone or in combination with other 
pharmacologic compounds, with the aim of maintaining the 
underlying disease in a clinically controlled state. On another 
front, FTIs seem optimal as postremission therapy for AML 
in elderly patients or those with other poor-risk features. 
Although there are limited data to suggest synergistic or 
Table 1 Studies of phase I and II with tipifarnib as a single agent in acute myeloid leukemia and myelodysplastic syndrome
Reference Study  Dose Diagnosis  Patientsa age Response  Survivalb (median)
Karp et al 2001  Phase I  100–1200 mg × 2  AML, ALL,   34 patients  10/34 (29%) 
      CML-BC    AML: 8/25 (32%) 
Kurzrock et al 2003  Phase I  300 mg × 2  RA, RAEB,   20 patients  6/20 (30%) 
      RAEB-t, CMML  66 (50–83)  CR: 1, PR: 2, Imp: 3 
Kurzrock et al 2004  Phase II  600 mg × 2  RA, RAEB,   27 patients  3/27 (11%) 
      RAEB-t  66 (49–80)  CR: 2, PR: 1 
Lancet et al 2007  Phase II  600 mg × 2  AML  158 patients  22/158 (14%)  DFS (7.3 months)
        74 (34–85)  PR + Imp: 15  OS (18 months)
          CR + PR + Imp: 23% 
Harousseau et al 2007  Phase II  600 mg × 2  AML  252 patients  11/252 (4%)  OS (12 months)
        62 (18–85)  CR: 9, CRp: 2 
aEvaluable patients.
bSurvival in responders.
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML-CB, chronic myeloid leukemia in blast crisis; RA, refractory anemia; RAEB, refractory 
anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; CR, complete remission; Crp, com-
plete remission with incomplete platelet recovery; PR, partial remission; Imp, hematologic improvement.Biologics: Targets & Therapy 2007:1(4) 423
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additive effects, the combination of FTIs with chemotherapy 
represents another avenue of exploration.
Based on promising preliminary evidence of tolerability, 
biologic activity, and clinical response in some patients with 
AML, further studies with tipifarnib (as with other agent in 
this class) are warranted. The challenge will be to deﬁ  ne the 
use of these new agents – when in the course of disease they 
should be administered, and in what combinations with other 
therapies. In this setting, novel agents with nonoverlapping 
mechanisms of action are to be combined and represent a 
potential step toward increasing favorable results in AML. 
A related challenge remains identifying a sensitive sub-type 
of leukemia based on a speciﬁ  c genetic proﬁ  le. A common 
set of genes that were regulated by tipifarnib have been found. 
Expression of these candidate genes might be used as surrogate 
markers of drug activity. In addition, recent work has identi-
ﬁ  ed genes that may be predictive of resistance or response to 
tipifarnib. While these markers need to be further validated, 
their identiﬁ  cation represent an important advance in the ability 
to stratify patients based on their likelihood of response.
References
Alvarez RH, Kantarjian H, Garcia-Manero G, et al. 2006. Farnesyl trans-
ferase inhibitor (tipifarnib, Zarnestra; Z) in combination with standard 
chemotherapy with idarubicin (Ida) and cytarabine (ara-C) for patients 
(pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk 
myelodysplastic syndrome (MDS). Blood, 108:565a–566a.
Appelbaum FR, Gundacker H, Head DR, et al. 2006. Age and acute myeloid 
leukemia. Blood, 107:3481–5.
Ashar HR, James L, Gray K, et al. 2000. Transferase inhibitors block the 
farnesylation of CENP-E and CENP-F and alter the association of 
CENP-E with the microtubules. J Biol Chem, 275:30451–7.
Aspuria PJ, Tamanoi F. 2004. The Rheb family of GTP-binding proteins. 
Cell signal, 16:1105–12.
Basso AD, Mirza A, Liu G, et al. 2005. The farnesyl transferase inhibitor 
(FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR 
signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor 
activity. J Biol Chem, 280:31101–8.
Basso AD, Kirschmeier P, Bishop WR. 2006. Farnesyl transferase inhibi-
tors. J Lipid Res, 47:15–31.
Boguski MS, McCormick F. 1993. Proteins regulating Ras and its relatives. 
Nature, 366:643–54.
Bonni A, Brunet A, West AE, et al. 1999. Cell survival promoted by the 
Ras-MAPK signaling pathway by transcription-dependent and -inde-
pendent mechanisms. Science, 286:1358–62.
Bos JL. 1989. Ras oncogenes in human cancer: a review. Cancer Res, 
49:4682–9.
Brunner TB, Hahn SM, Gupta AK, et al. 2003. Farnesyltransferase inhibi-
tors: An overview of the results of preclinical and clinical investigations. 
Cancer Res, 63:5656–68.
Burgering BM, Coffer PJ. 1995. Protein kinase B (c-Akt) in phosphatidy-
linositol-3-kinase signal transduction. Nature, 376:599–602.
Caplan AJ, Cyr DM, Douglas MG. 1992. YDJ1p facilitates polypeptide 
translocation across different intracellular membranes by a conversed 
mechanism. Cell, 71:1143–55.
Cates CA, Michael RL, Stayrook KR, et al. 1996. Prenylation of oncogenic 
human PTP (CAAX) protein tyrosine phosphatases. Cancer Lett, 
110:49–55.
Cox AD, Toussaint LG III, Fiordalisi JJ, et al. 2001. Farnesyltransferase 
and geranylgeranyltransferase inhibitors – The saga continues. In: SM 
Sebti and AD Hamilton eds. Farnesyltransferase inhibitors in cancer 
therapy. Totowa, NJ: Humana Press Inc. p 255–73.
Cox AD, Der CJ. 2002. Farnesyltransferase inhibitors: promises and realities. 
Curr Opin Pharmacol, 2:388–93.
Crul M, de Klerk GJ, Swart M, et al. 2002. Phase I clinical and pharma-
cologic study of chronic oral administration of the farnesyl protein 
transferase inhibitor R115777 in advanced cancer. J Clin Oncol, 
20:2726–35.
Davies RJ. 1995. Transcriptional regulation by MAP kinases. Mol Reprod 
Dev, 42:459–67.
Du W, Prendergast GC. 1999. Geranylgeranylated RhoB mediates sup-
pression of human tumor cell growth by farnesyltransferase inhibitors. 
Cancer Res, 59:5492–6.
Elam C, Hesson L, Vos MD, et al. 2005. RRP22 is a farnesylated, nucleo-
lar, Ras-related protein with tumor suppressor potential. Cancer Res, 
65:3117–25.
Ellis S, Mellor H. 2000. Regulation of endocytic trafﬁ  c by Rho family 
GTPases. Trends Cell Biol, 10:85–8.
End DW. 1999. Farnesyl protein transferase inhibitors and other therapies target-
ing the Ras signal transduction pathway. Invest New Drugs, 17:241–58.
End DW, Smets G, Todd AV, et al. 2001. Characterization of the antitumor 
effects of the selective farnesyl protein transferase inhibitor R115777 
in vivo and in vitro. Cancer Res, 61:131–7.
Estey EH, Thall PF, Wang XM, et al. 2006. Comparison of survival times 
after administration of tipifarnib or Ara-C-containing therapy, to 
older patients with newly-diagnosed acute myeloid leukemia. Blood, 
108:217b.
Fenaux P, Raza A, Mufti GJ, et al. 2007. A multicenter phase 2 study of 
the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk 
myelodysplastic syndrome. Blood, 109:4158–63.
Gau CL, Kato-Stankiewicz J, Jiang C, et al. 2005. Farnesyl-transferase 
inhibitors reverse altered growth and distribution of actin ﬁ  laments in 
Tsc-deﬁ  cient cells via inhibition of both rapamycin-sensitive and -insen-
sitive pathways. Mol Cancer Ther, 4:918–26.
Harousseau JL, Lancet JE, Reiffers J, et al. 2007. A phase 2 study of the 
oral farnesyltransferase inhibitor tipifarnib in patients with refractory 
or relapsed acute myeloid leukemia. Blood, 109:5151–6.
Kamasani U, Huang M, Duhadaway JB, et al. 2004. Cyclin B1 is a critical 
target of RhoB in the cell suicide program triggered by farnesyl trans-
ferase inhibition. Cancer Res, 64:8389–96.
Kantarjian H, O’Brien S, Cortes J, et al. 2006. Results of intensive chemo-
therapy in 998 patients aged 65 and older with acute myeloid leukemia 
or high-risk myelodysplastic syndrome: predictive prognostic models 
for outcome. Cancer, 106:1090–8.
Karp JE, Lancet JE, Kaufmann SH, et al. 2001. Clinical and biological 
activity of the farnesyltranferase inhibitor R115777 in adults with 
refractory and relapsed acute leukemias: a phase I clinical-laboratory 
correlative trial. Blood, 97:3361–9.
Karp JE, Gojo I, Greer J, et al. 2006. Tipifarnib (Zarnestra, R115777) as 
maintenance therapy for adults in complete remission (CR) following 
induction and consolidation therapies for poor-risk acute myelogenous 
leukemia (AML): a phase II trial. Blood, 108:780a–781a.
Karp JE, Feldman EJ, Morris L, et al. 2006b. Active oral regimen for elderly 
adults with newly diagnosed acute myelogenous leukemia (AML): 
phase I trial of oral tipifarnib (T) combined with oral etoposide (E) 
for adults age 70 who are not candidates for traditional cytotoxic 
chemotherapy (TCC). Blood, 108:130a.
Kho Y, Kim SC, Jiang C, et al. 2004. A tagging-via-substrate technology 
for detection and proteomics of farnesylated proteins. Proc Natl Acad 
Sci USA, 101:12479–84.
Khosravi-Far R, Cox AD, Kato K, et al. 1992. Protein prenylation: key to 
ras function and cancer intervention? Cell Growth Differ, 3:461–9.
Kirschbaum M, Selwyn Stein A, Tuscano J, et al. 2006. A phase I study of 
the farnesyltransferase inhibitor tipifarnib in a week-on week-off dose 
schedule in acute myelogenous leukemia. Blood, 108:551a.Biologics: Targets & Therapy 2007:1(4) 424
Thomas and Elhamri
Klippel A, Escobedo MA, Wachowicz MS, et al. 1998. Activation of phos-
phatidylinositol-3-kinase is sufﬁ  cient for cell cycle entry and promotes 
cellular changes characteristic of oncogenic transformation. Mol Cell 
Biol, 18:5699–711.
Kurzrock R, Kantarjian HM, Cortes JE, et al. 2003. Farnesyltransferase 
inhibitor R115777 in myelodysplastic syndrome: clinical and biologic 
activities in the phase I setting. Blood, 102:4527–34.
Kurzrock R, Albitar M, Cortes JE, et al. 2004. Phase II study of R115777, 
a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin 
Oncol, 22:1287–92.
Kurzrock R, Verstovsek S, Wright JJ, et al. 2006. Alternate week adminis-
tration of the farnesyltransferase inhibitor tipifarnib (ZARNESTRA®, 
R115777) in patients with myelodysplastic syndrome: results of a phase 
I study. Blood, 108:708a.
Lancet JE, Willman CL, Bennett JM. 2000. Acute myelogenous leuke-
mia and aging: clinical interactions. Hematol Oncol Clin North Am, 
14:251–67.
Lancet JE, Karp JE. 2003. Farnesyltransferase inhibitors in hematologic 
malignancies: new horizons in therapy. Blood, 102:3880–9.
Lancet JE, Gojo I, Gotlib J, et al. 2007. A phase 2 study of the farnesyltrans-
ferase inhibitor tipifarnib in poor-risk and elderly patients with previ-
ously untreated acute myelogenous leukemia. Blood, 109:1387–94.
Lara PN, Law LY Jr, Wright JJ, et al. 2005. Intermittent dosing of the farne-
syl transferase inhibitor tipifarnib (R115777) in advanced malignant 
solid tumors: a phase I California Cancer Consortium trial. Anticancer 
Drugs, 16:317–21.
Lebowitz PF, Casey PJ, Prendergast GC, et al. 1997. Farnesyltransferase 
inhibitors alter the prenylation and growth-stimulating function of 
RhoB. J Biol Chem, 272:15591–4.
Lebowitz PF, Sakamuro D, Prendergast GC. 1997b. Farnesyl transferase 
inhibitors induce apoptosis of Ras-transformed cells denied substratum 
attachment. Cancer Res, 57:708–13.
Leith CP, Kopecky KJ, Godwin J, et al. 1997. Acute myeloid leukemia in the 
elderly: assessment of multidrug resistance (MDR1) and cytogenetics 
distinguishes biologic subgroups with remarkably distinct responses to 
standard chemotherapy. A Southwest Oncology Group study. Blood, 
89:3323–9.
Liao H, Winkfein RJ, Mack G, et al. 1995. CENP-F is a protein of the 
nuclear matrix that assembles onto kinetochores at late G2 and is rapidly 
degraded after mitosis. J Cell Biol, 130:507–18.
Liu AX, Rane N, Liu JP, et al. 2001. RhoB is dispensable for mouse 
development, but it modiﬁ  es susceptibility to tumor formation as well 
as cell adhesion and growth factor signaling in transformed cells. Mol 
Cell Biol, 21:6906–12.
Löwenberg B, Downing JR, Burnett A. 1999. Acute myeloid leukemia. 
N Engl J Med, 41:1051–62.
Lowy DR, Willumsen BM. 1993. Function and regulation of ras. Annu Rev 
Biochem, 62:851–91.
MacKenzie KL, Dolnikov A, Millington M, et al. 1999. Mutant N-ras 
induces myeloproliferative disorders and apoptosis in bone marrow 
repopulated mice. Blood, 93:2043–56.
Mazure NM, Chen EY, Laderoute KR, et al. 1997. Induction of vascular 
endothelial growth factor by hypoxia is modulated by a phosphati-
dylinositol-3-kinase/Akt signaling pathway in Ha-ras-transformed 
cells through a hypoxia inducible factor-1 transcriptional element. 
Blood, 90:3322–31.
Morgan MA, Ganser A, Reuter CWM. 2003. Therapeutic efﬁ  cacy of pre-
nylation inhibitors in the treatment of myeloid leukemia. Leukemia, 
17:1482–98.
Nagata H, Hansen WJ, Freeman B, et al. 1998. Mammalian cytosolic DnaJ 
homologues affect the hsp70 chaperone-substrate reaction cycle, but 
do not interact directly with nascent or newly synthesized proteins. 
Biochemistry, 37:6924–38.
Punt CJ, van Maanen L, Bol CJ, et al. 2001. Phase I and pharmacokinetic 
study of the orally administered farnesyl transferase inhibitor R115777 
in patients with advanced solid tumors. Anticancer Drugs, 12:193–7.
Raponi M, Belly RT, Karp JE, et al. 2004. Microarray analysis reveals 
genetic pathways modulated by tipifarnib in acute myeloid leukemia. 
BMC Cancer, 4:56–68.
Raponi M, Harousseau JL, Lancet JE, et al. 2007. Identification of 
molecular predictors of response in a study of tipifarnib treatment in 
relapsed and refractory acute myelogenous leukemia. Clin Cancer 
Res, 13:2254–60.
Ridley AJ, Hall A. 1992. The small Gtp-binding protein Rho regulates 
the assembly of focal adhesions and action stress ﬁ  bers in response to 
growth factors. Cell, 70:389–99.
Rowinsky EK, Windle JJ, Von Hoff DD. 1999. Ras protein farnesyl-trans-
ferase: A strategic target for anticancer therapeutic development. J Clin 
Oncol, 17:3631–52.
Rowe JM. 2000. Treatment of acute myelogenous leukemia in older adults. 
Leukemia, 14:480–7.
Sinensky M, Fantle MK, Dalton M. 1994. An antibody which speciﬁ  cally 
recognizes prelamin A but not mature lamin A: application to detec-
tion of blocks in farnesylation-dependent protein processing. Cancer 
Res, 54:3229–32.
Suzuki N, Urano J, Tamanoi F. 1998. Franesyltransferase inhibitors induce 
cytochrome c release and caspase 3 activation preferentially in trans-
formed cells. Proc Natl Acad Sci USA, 95:15356–61.
Venet M, End D, Angibaud P. 1998. Farnesyl protein transferase inhibi-
tor ZARNESTRA R115777 – history of a discovery. Curr Top Med 
Chem, 3:1095–102.
Wang J, Kirby CE, Herbst R. 2002. The tyrosine phosphatase PRL-1 local-
izes to the endoplasmic reticulum and the mitotic spindle and is required 
for normal mitosis. J Biol Chem, 277:46659–68.
Wheeler AP, Ridley AJ. 2004. Why three Rho proteins? RhoA, RhoB, 
RhoC, and cell motility. Exp Cell Res, 301:43–9.
Whyte DB, Kirschmeier P, Hockenberry TN, et al. 1997. K- and N-Ras are 
geranylgeranylated in cells treated with farnesyl protein transferase 
inhibitors. J Biol Chem, 272:14459–64.
Yao X, Anderson KL, Cleveland DW. 1997. The microtubule-dependent 
motor centromere-associated protein E (CENP-E) is an integral com-
ponent of kinetochore corona ﬁ  bers that link centromeres to spindle 
microtubules. J Cell Biol, 139:435–47.
Zhang FL, Kirschmeier P, Carr D, et al. 1997. Characterization of Ha-Ras, 
N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl 
protein transferase and geranylgeranyl protein transferase type I. J Biol 
Chem, 272:10232–9.
Zhu K, Gerbino E, Beaupre DM, et al. 2005. Farnesyltransferase inhibitor 
R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce 
apoptosis and mitotic arrest and to inhibit tumor growth of multiple 
myeloma cells. Blood, 105:4759–66.
Zimmerman TM, Harlin H, Odenike OM, et al. 2004. Dose-ranging phar-
macodynamic study of tipifarnib (R115777) in patients with relapsed or 
refractory hematologic malignancies. J Clin Oncol, 22:4816–22.
Zujewski J, Horak ID, Bol CJ, et al. 2000. Phase I and pharmacokinetic 
study of farnesyl protein transferase inhibitor R115777 in advanced 
cancer. J Clin Oncol, 18:927–41.